Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lucid Diagnostics (LUCD) EPS (Weighted Average and Diluted) (2022 - 2025)

Lucid Diagnostics' EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.1 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 60.0% year-over-year to -$0.1; the TTM value through Sep 2025 reached -$0.88, up 22.12%, while the annual FY2024 figure was -$1.05, 16.67% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.1 in Q3 2025 per LUCD's latest filing, down from -$0.08 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.08 in Q2 2025 to a low of -$0.52 in Q1 2025.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$0.3, with a median of -$0.31 recorded in 2023.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 65.22% in 2025 against a maximum downside of 30.0% in 2025.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.4 in 2022, then soared by 37.5% to -$0.25 in 2023, then rose by 28.0% to -$0.18 in 2024, then surged by 44.44% to -$0.1 in 2025.
  • Per Business Quant, the three most recent readings for LUCD's EPS (Weighted Average and Diluted) are -$0.1 (Q3 2025), -$0.08 (Q2 2025), and -$0.52 (Q1 2025).